Document:

Prepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.18    
  

 
 

MODIFICATION TO EMPLOYMENT AGREEMENT    
  

    This Modification to Employment Agreement ("Modification") is dated for identification purposes only as of the 20th day of September 1996 and is made by and
between STAAR Surgical Company, a Delaware corporation, located at 1911 Walker Avenue, Monrovia, California 91016 (the "Company") and Steven L. Ziemba, whose address is 20845 High Country
Drive, Diamond Bar, California 91789 (the "Executive") based on the following: 

 
 

RECITALS    
  

    A.  On January 1, 1994 the Executive agreed to render services to the Company through December 31, 1996 on
the terms and subject to the conditions set forth in that certain "Employment Agreement" signed by the Executive and by the Company. 

    B.  Pursuant to paragraph 12(c)(i) of the Employment Agreement, the Company and the Executive wish to modify its
terms and conditions. 

    NOW, THEREFORE, in consideration of the foregoing and of the mutual promises contained in this Modification, the Company and the
Executive agree as follows: 

 
 

AGREEMENT    
  

    1.  Modification of Employment Term.  Paragraph 2 of the Employment Agreement shall be modified to
state: 

    Company
hereby employs Executive pursuant to the terms of this Agreement and Executive hereby accepts employment with the Company pursuant to the terms of this Agreement for the
period beginning on January 1, 1994 and ending on December 31, 2001. 

    2.  Grant of Additional Stock Options.  There shall be added to Paragraph 6(c) of the Employment
Agreement a second paragraph which shall state the following: 

Executive
shall be included in the 1996 STAAR Surgical Company Employee Non-Qualified Stock Option Plan (the "Plan") adopted by Company. Pursuant to the terms of the Plan, Executive shall be entitled
to purchase fifty thousand (50,000) shares of Company's common stock, which options shall vest over a period of five (5) years, ten thousand (10,000) shares each on January 1, 1997,
January 1, 1998, January 1, 1999, January 1, 2000 and January 1, 2001. The purchase price per share shall be $12.50. Stock issued pursuant to the Plan shall be restricted
stock, although Company shall reserve the right to issue registered shares if it so decides. Executive agrees to be bound by the terms of the Plan as adopted. These options shall be non-qualified
stock options. 

    3.  Severance Pay Upon Change of Control.  Paragraph 6(d) of the Employment Agreement shall be modified
to state: 

Upon
the sale or disposition by Company of substantially all of its business or assets or the sale of the capital stock of Company in connection with the sale or transfer of a controlling interest in
Company to a third party or the merger or consolidation of Company with another corporation as part of a sale or transfer of a controlling interest in Company to a third party, Executive shall
receive, as additional compensation and not in lieu of his rights under this Agreement, two (2) years' salary. "A controlling interest" shall be defined as 50% or more of the common stock of
the Company. "Two (2) years' salary" shall be defined as only the cash compensation paid to Executive pursuant to subparagraph (a) above, as it may be modified from time to time, and
shall not include employee benefits, incentive stock options, automobile allowance or debt forgiveness, if any. Executive shall be entitled to receive this additional compensation if Executive's
employment is terminated as a result of the change of control described herein or, if Executive, at Executive's election, terminates his employment as a result of such change of control. 

    4.  Modification to Termination Provision.  The first sentence of paragraph 10(b) shall be
modified to state: "Executive may, in his sole but reasonable judgment, terminate this Agreement if Executive determines that Company
has . . . ." 

    5.  All Other Terms and Conditions to Remain the Same.  The Company and the Executive agree that all
other terms and conditions of the Employment Agreement shall remain the same. 

    IN WITNESS WHEREOF, the parties have executed this Modification on the 25th day of September, 1996. 

	 	 	"Company"
	

 	
 	
STAAR Surgical Company
	

 	
 	

By:	
 	

/s/ JOHN R. WOLF   
 John R. Wolf
	

 	
 	
"Executive"
	

 	
 	

 	
 	

/s/ STEVEN L. ZIEMBA   
 Steven L. Ziemba

QuickLinks

Exhibit 10.18

MODIFICATION TO EMPLOYMENT AGREEMENT

RECITALS

AGREEMENTPrepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

SECOND MODIFICATION TO EMPLOYMENT AGREEMENT    
  

    This Second Modification to Employment Agreement ("Modification") is dated as of the 6th day of October 2000 and is made by and between STAAR Surgical
Company, a Delaware corporation, (the "Company") and Steven L. Ziemba (the "Executive") based on the following: 

 
 

RECITALS    
  

    A.  On January 1, 1994 the Executive agreed to render services to the Company on the terms and subject to the
conditions set forth in that certain "Employment Agreement" signed by the Executive and by the Company. 

    B.  Pursuant to paragraph 12(c)(i) of the Employment Agreement, the Company and the Executive wish to
modify its terms and conditions. 

    NOW, THEREFORE, in consideration of the foregoing and of the mutual promises contained in this Modification and other
good and valuable consideration, the receipt and sufficiency of which is acknowledged, the Company and the Executive agree as follows: 

 
 

AGREEMENT    
  

    1.  Modification to Paragraph 6(d).  Paragraph 6(d) shall be deleted in its entirety and
the following shall appear in its place: 

Election by Company due to a Change of Control. If Executive's employment is terminated by Company due to the sale or disposition by Company of
substantially all of its business or assets or the sale of the capital stock of Company in connection with the sale or transfer of a controlling interest in Company to a third party or the merger or
consolidation of Company with another corporation as part of a sale or transfer of a controlling interest in Company to a third party, Executive shall receive, in lieu of any other rights or benefits
under this Agreement, one (1) year's salary, and any option held by Executive which is unvested on the date of termination shall immediately vest. "A controlling interest" shall be defined as
50% or more of the common stock of the Company. "One (1) year's salary" shall be
defined as only the cash compensation paid to Executive pursuant to subparagraph 4(a), as it may be modified from time to time, and shall not include employee benefits, stock options, automobile
allowance or debt forgiveness, if any. 

    2.  All Other Terms and Conditions to Remain the Same.  The Company and the Executive agree that all
other terms and conditions of the Employment Agreement, as amended, shall remain the same. 

    IN WITNESS WHEREOF, the parties have executed this Modification as of the date first written above. 

	 	 	"Company"

STAAR Surgical Company
	

 	
 	

By:	
 	

/s/ ANDREW F. POLLET   
 Andrew F. Pollet, Chairman of the Board
	

 	
 	
"Executive"
	

 	
 	

 	
 	

/s/ STEVEN L. ZIEMBA   
 Steven L. Ziemba

QuickLinks

SECOND MODIFICATION TO EMPLOYMENT AGREEMENT

RECITALS

AGREEMENT<PAGE>

                           Patent license agreement.

     The Eye Microsurgery Entersectoral Research and Technology Complex,
Moscow, Russia, represented by General Director Mr. Fedorov S.N., from here
an referred to as the "Licenser", and STAAR Surgical AG, a Swise corporation,
Hidau, Switzerland represented by President Mr. Vladimir Feingold and
Director Mr. John R. Wolf, from here an referred to as the "Licensiate",
taking into account that the Licenser possesses the "Technology for Producing
Collagen-Based Cross-Linked Drain", and the Licensiate wants to acquired the
license on this technology.

     The Licenser and Licensiate agree as follow undestndings, which shall
become in force since 1.1.96.

                                   Article 1.

DEFENITIONS:  For the purposed of this Agreement the following expressions
have the meanings indicated below:

     1.1  "Product" is the product described in Appendix 1.

     1.2.  "Patent" is the patent whose detailed description is given in
Appendix 2 and also future inventions are given in Appendix 3.

     1.3.  "Technical knowledge" stands for technical information, know-haw,
manufacturing technology, technical data, material specifications, and other
information used by the Licenser during the manufacture of the product
(or which is necessary and sufficient for the Licensiate to make the Product
according to the standart and quality of the product made by the Licenser),
(including any improvements obtained during the validity period of this
Agreement).

     1.4  "Territory" covers all countries listed in Appendix 5.

     1.5  "Exclusive territory" covers the countries listed in part 1 of
Appendix 4.

     1.6. "Non-exclusive territory" covers the countries listed

<PAGE>

                                      -2-

in part 2 of Appendix 4.

     1.7  "Year" means any period of time of 12 months starting from the date
of executing the Agreement.

                                       Article 2.

     The Licenser is an owner of Patents listed in Appendix 2, and has the
right of disposal of the said Patents.

     No prior transfers occurred.  No share or total property covered by the
Patents have been transfered, yielded or alienated to any person except for
the Licensiate according to this Agreement.

     The Licenser has not given any license under listed in Appendix 2
patents yet.  The Licenser's rights are free from the right of detension,
pledge, backing interest or other proprietary burdans.  The Licenser
disclosed to any third legal or phisical person no confidential information,
production secrets or know-how, relating to the technical aspects of the
Patents, exept claim 3 in Appendix 1, on which Licenser conduct the joint
measures only with Licensiate.

     Furthermore, the Licenser has production secrets and experience
(know-how) concerning the subject matter of this license.

                                   Article 3.

       Transference of rights on the Patents and patent applications.

     For valuable consideration, the receipt and sufficient of which are
confirmed by the Licensiate, the Licenser assigns to the Licensiate its
entire and exclusive rights, title, interest, and material right relating to
the "Patent" described in Appendix 2, and also the future Patents described
in Appendix 3 to this Agreement.  The Licensiate shall acquire the entire and
exclusive right belonging to the Licenser to the Licensiates benefit for the
whole term of validity of the Patent.

<PAGE>

                                      -3-

                                  Article 4.

     I.  Technical field of application.

     The license for the "Technology for Producing Collagen-Based
Cross-Linked Drains" relates to the entire sphere of application of the
inventions mentioned in the patents and listed in the Appendix 2 and 3, as
well as everything that definitively stems from these inventions.

     The Parties shall infirm each other openly and without any reservations
on the possible fields of application of the inventions, that were unknown to
the Parties at the day of conclusion of the Agreement, and, as proved later,
can be carried by the Parties into effect and/or can be wanted for
realization.

     II.  License type.

     The Patent deals with an exclusive license:

     (a)  In so doing, however, the Licenser keeps the right of manufacturing
the products covered by the license, to use them or sell on a non-exclusive
territory specified in part 2 of Appendix 4.

     (b)  Furthermore, the Licenser reserves a right of realizing the product
by the license in its branches and joint ventures, existing or to be created,
on the exclusive specified in part 1 of Appendix 4, without right of salling
to any another third person on the exclusive territory.  This thesis in force
only for cases when operation in medical branches and joint ventures is
realized surgeons, these surgeons works in Eye Microsurgery Intersectoral
Research and Technology Complex and officially sents on the contract with the
Licenser.

     (c)  This license is intended for manufacture, use and sale.

                                 Article 5.

<PAGE>

                                      -4-

                             Territory covered by the Agreement.

     The license was granted for use on the exclusive territiry (see Appendix
4).

     The Licensiate has the right of production on other countries including
those where the Licenser has no protective rights.

     The Licenser shall prevent export to the countries which belongs to
non-exclusive territory.

     If, in spite of this, the export shall be effected, the Licensiate shall
have the right of cancelling the Agreement by means of a simple written
message.

     The Licenser shall pay conventional penalty equal to 20-fold price of
the export delivery, which is inadmissible by virtue of the above statements.

     In the equivalent manner the Licenser shall put on its customers an
obligation to avoid export of the subject matter of this license, because it
is inadmissible according to the above statements, and to pay to it a
conventional penalty in an amount of 20-fold price of the exported goods in
every case of infringement.  This sum the Licenser shall transfer to
Licensiate.

                                  Article 6.

                                  License registration.

     Each Party shall have the right of registering the license in the Patent
Office provided that such registration of the country or countries, with
respect to which the license is given.  The Licenser shall transfer to the
licensiate the authority and approval swich is necessary for this purpose.
The registration fee shall be covered by the licensiate.

                                  Article 7.

                       Drawings and descriptive documents.

<PAGE>

                                      -5-

     The Licenser shall give to the Licensiate all existing drawings, plans,
quality inspection system, and other technical documents required for the
manufacture under license.  These documents may be dublicated.  The
Licensiate shall treat these drawings and documents as secret materials
during the entire term of action of this Agreement and after it will be
expired.

                                  Article 8.

                                  Mastering.

     The Licenser is released from responsibility for the risk associated
with the industrial-scale mastering of the manufacture under license, for
which the Licensiate is responsible.

     The Licenser is released from responsibility for the risk of the
commercial realization of the invention.  The realisation risk is taken
solely by the Licensiate.

                                        Article 9.

     I.  Quality of products manufactured under license.

     The Licesiate shall manufacture the products under license whose quality
is the same as those manufactured by Licenser.  The licenser provides all
necessary consultations and information accumulated from its own experience.

     II.  Consequences of poor quality of products manufactured under license.

     The Licenser has the right of quality monitoring so as to check of the
products manufactured under license correspond to the quality established by
the Agreement.

     III.  Sublicenses.

     1.  The Licensiate has the right to offer sublicenses.

<PAGE>

                                      -6-

     2.  In case of selling of sublicense the earning is distributed between
the Licenser and Licensiate of this Agreement in equal parts.

                                  Article 10.

                               Confidentiality.

     The parties concluding this Agreement agree that they consider as secret
all technical and technological information relating to the Production under
license and made available to the Licensiate.

     The information obtained from the Licenser is kept in secret during the
entire validity period of the Agreement and after the validity period of this
Agreement is expired.

     The Licensiate has the right to use free of charge the entire technical
information after the validity period of this Agreement is expired.

                                  Article 11.

             Improvements and amedments of the subject of license.

     The Licenser is obliged to inform the Licensiate about all modifications
and improvements, that shall be made during the validity period of this
Agreement and concerning the subject matter of the license.

     If the amendments and improvements shall lead to a patentable invention,
it must be transferred to the Licensiate free of charge with simultaneous
prolongation of the period validity under definite conditions.

                                 Article 12.

                              Technical assistance.

     The Licenser submits to the Licensiate scrupulously and unconditionally
all technical assistance and necessary advisiment.

<PAGE>

                                      -7-

     The Licenser, at the expense of the Licensiate, shall sent specialists
under the following conditions:

     - the skill of the sent personnel must be sufficient for solving the
technical problems that may arise with respect to the Agreement;

     - the period of working shall be agreed later;

     - the Licensiate shall cover the expenses associated with the
accommodation, transportation and insurance of the expartiate personnel.

     The Licensiate shall pay the personnel wages in US dollars in an amount
twice the sum they have in their own country.

                                  Article 13.

            Amendments and improvements to be made by Licensiate.

     The amendments and improvements that shall be made by the Licensiate
with respect to the subject of the license may be made without special
permission of the Licenser.  The Licensiate has the right to perform the
amendments and improvements without Licenser's permission provided that the
Licensiate alone shall be responsible for these amendments and improvements.

                                  Article 14.

                   Payment with conclusion of the Agreement.

     14.1  The Licensiate shall pay to the Licenser on the corresponding
account of Russian "Vneshtorgbank" No 608-205-524 in the National Republican
Bank of New-York, USA, with an order to credit for the above sum account No
67087105/001 of the Eye Microsurgery Intersectoral Research and Technology
Complex in the "Vneshtorgbank" Moscow the sum of the three hundred fifty
thousand US dollars (350.000 USD) as a single payment within 10 days when
this Agreement come into force and before transference of documents and
draughts.  Documentation shall be transferred to the Licensiate when said sum
comes to the specified bank.

<PAGE>

                                      -8-

     14.2.  The sum of two hundred fifty thousand US dollars (250.000 USD)
shall be payed by the Licensiate on the before specified account within 10
dais after receipt if the signed by the Licenser acts about full concession
of the patent rights.

     14.3.  The sum of one hundred fifty thousand US dollars (150.000 USD)
shall be payed by the Licensiate on the before specified account within 10
days after receipt of the official decision of the US Patent Office about
registration of full concession on the Licensiate name.

                                  Article 15.

                                   Royalty.

     The Licensiate pays to the Licenser royalty depending on the volume of
year sales and as compensation of license price.  Royalty pays as a
percentages of sums paid by its buyers for the products made under conditions
of free plant without packing, as well as the sums obtained from learning the
technology used in ophthalmosurgery with deduction of trade taxes.

     Then the volume of sales:

                     to 25.000 pieces...................5.0%
                from 25.000 to 50.000 pieces............4.5%
                from 50.000 to 75.000 pieces............4.0%
                from 75.000 to 100.000 pieces...........3.5%
                     more then 100.000 pieces...........3.0%

                                  Article 16.

                   Appearance of the right for license payment.

     The right for license payment arises as soon as the Licensiate gets
payment from the buyer.

                                  Article 17.

<PAGE>

                                      -9-

                                Taxes and duties.

     If direct sales taxes is taken in the Licensiates country, or in the
country on non-exclusive territory, they are paid by the Licensiate.

                                  Article 18.

                             Accounting and reports.

     The Licensiate is obliged to keep account in special books, in which it
shall put the accurate number of the products manufactured under license
according to this Agreement, original numbers applied onto the machines and
all other data needed for calculation of the license prise.  The Licenser has
the right to give an order to audit these books and their correspondence with
the general accounting of the Licensiate through an auditor by the Licensiate.

     The Licensiate shall bear the expenses associated with such an audit.

                                    Article 19.

                         Calculation on license payments.

     The calculations on the license payments are performed at the end of
each quarter of a calendar year.  The Licensiate shall send the complete data
on these calculations within a month following the day of their performance
and to remit the calculated sum within the same period.

     If the Licensiate exceeds a time limit for payment, the Licenser may
take annual interest of 6% within 60 days each quarter.

                                   Article 20.

                         Obligation on using the license.

     The Licensiate is obliged to use the license.

<PAGE>

                                      -10-

                                   Article 21.

                          Affaire on patent applications.

     The Licenser pledges oneself to continue affair in Russia and other
countries on applications, patents on witch are not given by Patient Offices.

     The Licensiate pledges oneself to give to the Licenser the copies of
decision of Patient Offices about full transference of patient rights on
inventions, within 10 days since the moment of receipt by the Licensiate.

                                  Article 22.

                                Patent support.

     The Licensiate shall support the Patent that is put as a base of
this license Agreement.

                                  Article 23.

                            Patent rights protection.

     If the Patent is infringed by a third party and the Licenser becomes
aware such infringement, the Licenser shall promptly notify the Licensiate in
writing of such infringement or unfair competition. The Licensiate, in its
sole discretion, shall determine if it shall defend the Patent infringement
or unfair competition, it shall so notify the Licenser.  The Licenser agrees
to cooperate and assist in prosecution of any action in the nature of unfair
competition or patent infringement prosecuted by the Licensiate.

     The Licenser shall support the Licensiate, first of all, if such a
support is provided by the property right of the respective country.  The
Licenser shall give the Licensiate all necessary authority and documents that
shall enable the Licensiate to bring a suit and to present witnesses or

<PAGE>

                                     -11-

coauthors and also to take an active part in infringement proceeding.

     The party making a decision to suit the third party bears possible
expenses in preparation and conduction of legal proceedings.

                                  ARTICLE 24.

             Licensiates obligation to defence the patent rights.

     The Licensiates commit itself that neither it personally nor its
authorized person shall dispute the patent rights put in the base of this
Agreement except the cases.

                                  ARTICLE 25.

             Cancellation of Patent:  its effect on the Agreement.

     If the protective rights setting up the base of this Agreement are
cancelled by the claim of a third party, the paid license payments in no case
shall be reimbursed, however, if the term of their payment does not yet come,
they shall not be taken.

                                  ARTICLE 26.

                               Agreement Validity

      The Agreement validity period is equal to that of the patent validity.

     The Agreement shall come into force from the moment of its signing.

                                  ARTICLE 27.

                                 Force Majeure.

     Either party is relieved from liability for partial or complete
non-performance of their obligations under present
<PAGE>

                                     -12-

Agreement is some circumstances that aroused independent of their will.

     The circumstances caused by events that were independent of the will of
the parties of this Agreement so that the fair party could not avoid or
eliminate, are considered as cases realising this party from its obligations,
if they take place after signing the Agreement and prevent its fulfillment
completely of partially.

     The cases of unsurmountable force are reduced to the following events:
war, military actions, revolts, mobilization, road accidents and natural
disasters, legal acts of authorities affecting the fulfillment of the
obligations, and all other events which are considered as circumstances of
unsurmountable force by a competent arbitration court.

                                  ARTICLE 28.

                            Applicable Legislation.

     This Agreement is applicable to the Swiss Law.

                                  ARTICLE 29.

                        Legal Protection and Arbitration

     If any dispute or difference shall arise between the parties to this
Agreement as to any matter or thing arising in connection with the Agreement
then the aggrieved party shall give to the other party a notice in writing
setting out in full detailed particulars of the dispute or difference.  Upon
receipt of the notice the parties shall agree to appoint the International
Chamber of Commerce shall appoint a date, time and venue (unless the parties
agree to a date, time and venue) for mediation proceedings to be held to
discuss in detail the dispute or difference.  The parties shall not be legally
represented at the mediation proceedings but shall present, in their own
manner, with the assistance or witnesses and documentary evidence, the
<PAGE>

                                     -13-

details of their respective cases.  If, at the conclusion of the mediation
proceedings the parties fail to resolve the dispute or difference, either
party may give to the other party, within 14 days, a notice stating that at
the expiration of 30 days it will proceed to have the dispute of differents
referred to a court of competent jurisdiction in Switzerland (or another
country as the parties agree) and at the expiration of such 30 days may so
proceed.

                                  ARTICLE 30.

                                 Miscellaneous

     1.   This Agreement covers all agreed provisions and aspects of the
License Agreement.  It has no any additional promises or terms as a condition
of execution of the License Agreement, along with other terms except those
stated above.  All preliminary agreements, promises, negotiations or
presentations, which are not included into this License Agreement shall not
be valid from the moment of its singing.  Any subsequent agreement, which
shall lead to a change or cancellation of this License Agreement, shall be
valid solely if it is made in writing and signed by the authorized
representatives of both parties.

     2.   Successors and Assigns.

     This Agreement and all of its provisions shall be binding and inure to
the benefit of the successors and assigns of the parties.

     If not states specially in this Agreement, all requested notices,
requirements, questions, agreed statements, approvals, or other
communications between the partners shall be made in writing and delivered:
(A) by a messenger (such a message is delivered personally), (B) by telegraph
or air express mail (in so doing the messages are sent by R-mail), (C)
electronic mail, fax or telephone provided that the recipient has a
compatible device or confirms the receipt of the message (in this case it is
assumed that the

<PAGE>

                                     -14-

transmission or reception of the message will be confirmed), or (D) by
mailing a registered or valuable letter (in this case it is assumed that the
letter shall be delivered at the 14th day after dispatching).  The messages
are sent to the following addresses:

     Licensiate:  STAAR Surgical AG
                  Hauptstrasse 104
                  CH 2560 Hidau
                  Switzerland
                  Attn:  President
                  A copy to address:
                  STAAR Surgical Company
                  1911 Walker Avenue
                  Monrovia, California  91016
                  Attn:  President - Chief Executive Officer

     Licenser:    Eye Microsurgery Intersectoral Research and Technology
                  Complex, Moscow, Russia, 127486, Beskudnikovsky bulvar, 59-a

     The above addresses may be changed by notifying the other party about
this action, as mentioned above.

     3.   The right of signing the document.

     Each party states that it has all necessary authority to sign this
License Agreement.  All individual signings of this Agreement for the party
that is a corporation, company or another legal counsel, or a signature of a
proxy or another authorized person, is accompanied by confirmation of the
fact that this person has the right of putting his signature under the given
document on behalf of a respective organization or its manager.

     4.   Counterpart Copies.

     This Agreement may be signed in counterpart or duplicate copies, and any
signed counterpart or duplicate copy shall
<PAGE>
                                     -15-

be equivalent to a signed original for all purposes.

     5.   Completeness of the Agreement.

     This is the entire agreement between the parties covering everything
agreed upon or understood between the parties covering everything agreed upon
or understood with respect to the subject matter of it.  There are no
promises, conditions, representations or terms of any kind as conditions or
inducements to the execution hereby or in effect between the parties other
than as herein set forth.  Any prior agreement, promises, negotiations or
representations not expressly set forth in this Agreement are of no force or
effect.  Any agreement hereafter made shall be ineffective to change, modify,
discharge or effect an abandonment of this Agreement in whole or in part
unless such agreement is in writing and signed by the party against whim
enforcement of the change, modification, discharge or abandonment is sought.

     6.   Preparation of Agreement.

     It is acknowledged that each party hereto either bad separate and
independent advice of counsel or the opportunity to avail itself of same.
This Agreement was prepared by the parties to it in conjunction with
counseling from their respective attorneys, or the opportunity to obtain such
counseling.  In light of these facts it is acknowledged that no party to this
Agreement shall be construed to be solely responsible for the drafting of it,
and therefore any ambiguity shall not be construed against any party as the
alleged draftsman of this Agreement.

     7.   Gender and Number.

     As used in this Agreement, the masculine, feminine, or neuter gender,
and the singular or plural number, shall include the others whenever the
context so indicate.

<PAGE>

                                     -16-

     8.   Headings.

     The titles and headings of the various sections of the Agreement are
intended solely for convenience of reference and are not intended solely for
convenience and are not intended to explain, modify, or place any
construction on any of the provisions of this Agreement.

     9.   No Waiver.

     The failure of a party to insist on the strict performance of any
covenant or duty required by this Agreement, or to pursue any remedy under
the Agreement, shall not constitute a waiver of the breach or the remedy.

     10.  Severability.

     If any part or provision of this Agreement shall be determined to be
invalid, illegal or unenforceable, then the remaining part of this Agreement
which can be separated from the invalid, illegal or unenforceable provision
shall continue in full force and effect, and the invalid, illegal or
unenforceable provision shall be construed as if they had never been
incorporated into this Agreement.

     This Agreement and all of its provisions shall be binding on and inure to
the benefit of the successors of the parties.

     11.  Counterparts and Facsimiles.

     For the convenience of the parties to this Agreement, this document may
be executed by facsimile signatures and in counterparts which shall together
constitute the agreement of the parties as one and the same instrument.

     This License Agreement is concluded in four authentic copies, two of
which are in English and in Russian, all copies has an equal juridical force.

     IN WITNESS WHEREOF, the parties thereto have executed this Assignment
Agreement on the day and year set forth opposite their respective signatures
below:

<PAGE>

                                     -17-

     "Licenser":    Eye Microsurgery Intersectoral Research
                    and Technology Complex
                    General Director, academician

                    /s/ [illegible]  S.N. Federov

     "Lecensiate":  STAAR Surgical AG
                    President and Director

                    _____________________Vladimir Feingold

                    Director

                    _____________________John R. Wolf

<PAGE>

                                     -18-

                                  APPENDIX N 1.

               Technology of production intraocular lenses from
                              collagen co-polimers

     Nowadays, intraocular correction is one of the basic medical treatment
method of vision body disease.

     Artifical eye linses are used not only when cataract, but also for
removal of refraction anomalies.

     Artifical eye lenses, which are implantated through small sizes, are
most perspective.  Several requirements are produced to artifical eye lenses
like elasticity, biocompatibility, low specific density and high solidity on
rupture.  Artifical eye lenses from collagen co-polimers corresponds to these
principles.

     Hight elasticity, hight solidity on rupture are the main quality of these
products.  It allows to make implantation as tool-making method so method of
injection also.

     Lenses, which are maked an special technology, passed experimental and
hospital tests successfully and inculcated in wide surgical practice as in
Eye Microsurgery Intersectoral Research and Technology Complex so in the
other Russian and CIS hospitals.
<PAGE>

                                     -19-

                                  APPENDIX N 2.

                                List of patents.

     1.   US patent N 5.286.829 (Russian application N 4745668)
"Biocompatible polymer material and a process for producing same", inventors
S.N. Fedorov, S.N. Bagrov, A.V. Osipov, E.A. Linnik, I.A. Maklakova, A.N.
Kosmynin, E.V. Larionov, priority 13.10.89, patentee - Eye Microsurgery
Intersectoral Research and Technology Complex.

     2.   Russian patent N 2033165 (Russian application N 4745668) "Process
for producing plastic material from collagen", inventors S.N. Fedorov, S.N.
Bagrov, A.V. Osipov, E.A. Linnik, I.A. Maklakova, A.N. Kosmynin, E.V.
Larionov, priority 13.10.89, patentee - Eye Microsurgery Intersectoral
Research and Technology Complex.

     3.   USSR Inventors Certificate N 1823178 (Russian application N
4881670) "Artificial eye lens and process of its implantation in back eye
camera", inventors S.N. Fedorov, V.K. Zuev, B.M. Aznabaev, priority 21.11.80.

     4.   USA patent N 5258025 (Russian application N 4881670) "Correctional
intraocular lens", inventors S.N. Fedorov, V.K. Zuev, B.M. Aznabaev, priority
21.11.80, patentee - Eye Microsurgery Intersectoral Research and Technology
Complex.

     5.   Germany laid-open application (Russian application N 4881670)
"Correctional intraocular lens", inventors S.N. Fedorov, B.M Aznabaev, V.K.
Zuev, priority 22.04.93, patentee - Eye Microsurgery Intersectoral Research
and Technology Complex.

     6.   Russian patent N 2033114 (Russian application
<PAGE>

                                     -20-

9302177), "Artificial eye lens", inventors S.N. Fedorov, V.K. Zuev, priority
22.04.93, patentee - Eye Microsurgery Intersectoral Research and Technology
Complex.

     7.   Notice of allowance in USA, application N 08.231.549 in USA
(Russian application N 93021277) from 27.06.95, "Correctional artificial eye
lens", inventors S.N. Fedorov, V.K. Zuev, priority 27.06.95, patentee - Eye
Microsurgery Intersectoral Research and Technology Complex.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]